CaPtivate Pharmaceuticals

Executive Summary

CaPtivate Pharmaceuticals is a private, development-stage biotechnology company leveraging its proprietary calcium phosphate (CaP) nanoparticle platform for vaccine adjuvants and drug delivery. Founded in 2018 and based in San Diego, the company aims to improve the efficacy and stability of vaccines and therapeutics across human and veterinary health. Its CaP technology offers advantages in biocompatibility, targeted delivery, and enhanced immune response. As a preclinical entity, CaPtivate is focused on validating its platform through proof-of-concept studies and seeking strategic partnerships. The company operates in the competitive drug delivery and nanotech space, with potential applications ranging from infectious disease vaccines to cancer immunotherapies. Key milestones will be demonstrating platform versatility and advancing a lead candidate toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q2 2026Lead Vaccine Candidate Preclinical Data Readout60% success
• Q3 2026Series A Funding Round Closing50% success
• H2 2026Strategic Partnership or Licensing Deal40% success